<?xml version="1.0" encoding="utf-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:types="http://xbrl.frc.org.uk/general/2019-01-01/types" xmlns:uk-ref="http://xbrl.frc.org.uk/general/2019-01-01/ref" xmlns:common="http://xbrl.frc.org.uk/general/2019-01-01/common" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:curr="http://xbrl.frc.org.uk/cd/2019-01-01/currencies" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:countries="http://xbrl.frc.org.uk/cd/2019-01-01/countries" xmlns:lang="http://xbrl.frc.org.uk/cd/2019-01-01/languages" xmlns:bus="http://xbrl.frc.org.uk/cd/2019-01-01/business" xmlns:accrep="http://xbrl.frc.org.uk/reports/2019-01-01/accrep" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:aurep="http://xbrl.frc.org.uk/reports/2019-01-01/aurep" xmlns:Q1="http://xbrl.org/2005/xbrldt" xmlns:direp="http://xbrl.frc.org.uk/reports/2019-01-01/direp" xmlns:core="http://xbrl.frc.org.uk/fr/2019-01-01/core" xmlns:FRS-102="http://xbrl.frc.org.uk/FRS-102/2019-01-01" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2010-04-20" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="application/xhtml+xml; charset=UTF-8" http-equiv="Content-Type" /><title>NEUROMEDICA_LIMITED - Accounts</title><style type="text/css">@page land { size:landscape; }@page port { size:portrait; }.pageFirst { page-break-after:always;  background-color:white;    border-top:1px solid black;  border-bottom:1px solid black;    border-left:1px solid black;    border-right:1px solid black;   } .portraitPage {    page:port;  width:21cm; height:29.7cm; page-break-after:always; background-color:white; border-top:1px solid black; border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; position:relative; } .landscapePage {  page:land;  width:29.7cm; height:21cm; page-break-after:always; background-color:white; border-top:1px solid black; border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; position:relative; } a.tooltip {color:black;text-decoration:none}a.tooltip span{display:none}a.tooltip:hover span{display:inline;position:absolute;z-index:5002;background:#ffffff}a.anchor {color:blue;}a.tooltipRTF {color:black;text-decoration:none;display:none}span:hover a.tooltipRTF {display:block;position:absolute;background:#ffffff}span.tooltipRTFtext {position:absolute;left:10;width:200;border:1pt solid black;text-align:left;font-weight:normal;z-index:5002;bottom:20;font-family:Arial;font-size:9;background-color:#FFFFCC; }.c,.crn,.cjn,.cln,.ccn,.crb,.cjb,.clb,.ccb,.crni,.cjni,.clni,.ccni,.crbi,.cjbi,.clbi,.ccbi{position:absolute;word-wrap:break-word}.crn,.cjn,.cln,.ccn,.crni,.cjni,.clni,.ccni{font-weight:normal}.crb,.clb,.cjb,.ccb,.crbi,.cjbi,.clbi,.ccbi{font-weight:bold}.crni,.cjni,.clni,.ccni,.crbi,.cjbi,.clbi,.ccbi{font-style:italic}.crn,.crb,.crni,.crbi{text-align:right}.cln,.clb,.clni,.clbi{text-align:left}.ccn,.ccb,.ccni,.ccbi{text-align:center}.cjn,.cjb,.cjni,.cjbi{text-align:justify}.fn0{font-size:0px}.fn1{font-size:10.4px;font-family:Arial}.fn2{font-size:15.2px;font-family:Arial}.fn3{font-size:12.8px;font-family:Arial}.fn4{font-size:6.4px;font-family:Arial}.fn5{font-size:9.6px;font-family:Arial}.fn6{font-size:0px;font-family:Arial}.sln{border-top:1px solid black}.dln{border-top:4px double black}.u{text-decoration:underline}ul,li{ margin-top:0px;margin-bottom:0px;margin-right:0px;margin-left:8px;   padding-top:0px;padding-bottom:0px;padding-right:0px;padding-left:8px;} </style></head><body xml:lang="en" style="background-color:white"><div class="pageFirst" style="height:727pt;width:516pt;"><div class="clb fn1" style="top:31.08pt;left:46.61pt;width:423.77pt;"></div><div class="crb fn1" style="top:52.31pt;left:43.61pt;width:420.55pt;">Company Registration Number <ix:nonNumeric contextRef="C" name="bus:UKCompaniesHouseRegisteredNumber">07316989</ix:nonNumeric> (England and Wales)</div><div class="ccb fn2" style="top:162.17pt;left:46.61pt;width:420.55pt;"><ix:nonNumeric contextRef="C" name="bus:EntityCurrentLegalOrRegisteredName">NEUROMEDICA LIMITED</ix:nonNumeric></div><div class="ccb fn2" style="top:188.45pt;left:46.61pt;width:420.55pt;">UNAUDITED FINANCIAL STATEMENTS</div><div class="ccb fn2" style="top:214.74pt;left:46.61pt;width:420.55pt;">FOR THE YEAR ENDED</div><div class="ccb fn2" style="top:230.02pt;left:46.61pt;width:420.55pt;">31 JULY 2019</div><div class="ccb fn2" style="top:260.84pt;left:46.61pt;width:420.55pt;">PAGES FOR FILING WITH REGISTRAR</div></div><div class="portraitPage" style="height:727pt;width:516pt;"><div class="clb fn1" style="top:31.08pt;left:46.61pt;width:423.77pt;"></div><div class="clb fn2" style="top:40.75pt;left:46.61pt;width:423.77pt;"><ix:nonNumeric contextRef="C" name="bus:EntityCurrentLegalOrRegisteredName">NEUROMEDICA LIMITED</ix:nonNumeric></div><div class="clb fn2" style="top:54.9pt;left:46.61pt;width:423.77pt;"></div><div class="clb fn3" style="top:69.04pt;left:46.61pt;width:423.77pt;">CONTENTS</div><div class="cln fn4" style="top:80.95pt;left:46.61pt;width:420.77pt;"></div><div class="clb fn3" style="top:86.91pt;left:46.61pt;width:423.77pt;"></div><div class="cln fn0 sln" style="top:98.82pt;left:46.61pt;width:420.77pt;"></div><div class="cln fn0 sln" style="top:695.49pt;left:46.61pt;width:420.77pt;"></div><div class="clb fn1" style="top:123.45pt;left:409.6pt;width:60.79pt;">Page</div><div class="cln fn1" style="top:156.46pt;left:46.61pt;width:362.98pt;">Directors' report</div><div class="cln fn1" style="top:156.46pt;left:409.6pt;width:57.79pt;">1</div><div class="cln fn1" style="top:200.49pt;left:46.61pt;width:362.98pt;">Accountants' report</div><div class="cln fn1" style="top:200.49pt;left:409.6pt;width:57.79pt;">2</div><div class="cln fn1" style="top:244.51pt;left:46.61pt;width:362.98pt;">Statement of financial position</div><div class="cln fn1" style="top:244.51pt;left:409.6pt;width:57.79pt;">3 - 4</div><div class="cln fn1" style="top:288.54pt;left:46.61pt;width:362.98pt;">Statement of changes in equity</div><div class="cln fn1" style="top:288.54pt;left:409.6pt;width:57.79pt;">5</div><div class="cln fn1" style="top:332.56pt;left:46.61pt;width:362.98pt;">Notes to the financial statements</div><div class="cln fn1" style="top:332.56pt;left:409.6pt;width:57.79pt;">6 - 10</div></div><div class="portraitPage" style="height:727pt;width:516pt;"><div class="clb fn1" style="top:31.08pt;left:46.61pt;width:423.77pt;"></div><div class="clb fn2" style="top:40.75pt;left:46.61pt;width:423.77pt;"><ix:nonNumeric contextRef="C" name="bus:EntityCurrentLegalOrRegisteredName">NEUROMEDICA LIMITED</ix:nonNumeric></div><div class="clb fn2" style="top:54.9pt;left:46.61pt;width:423.77pt;"></div><div class="clb fn3" style="top:69.04pt;left:46.61pt;width:423.77pt;">DIRECTORS' REPORT </div><div class="cln fn4" style="top:80.95pt;left:46.61pt;width:420.77pt;"></div><div class="clbi fn3" style="top:86.91pt;left:46.61pt;width:423.77pt;">FOR THE YEAR ENDED 31 JULY 2019</div><div class="clb fn1" style="top:98.82pt;left:46.61pt;width:423.77pt;"></div><div class="cln fn0 sln" style="top:108.5pt;left:46.61pt;width:420.77pt;"></div><div class="cln fn0 sln" style="top:695.49pt;left:46.61pt;width:420.77pt;"></div><div class="ccn fn5" style="top:701.96pt;left:46.61pt;width:420.77pt;">- 1 -</div><div class="cln" style="top:122pt;left:47pt;width:419pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">The directors present their annual report and financial statements for the year ended 31 July 2019.</span></p></div><div class="clb fn1" style="top:143.91pt;left:46.61pt;width:422.42pt;">Directors</div><div class="cln" style="top:155pt;left:47pt;width:419pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">The directors who held office during the year and up to the date of signature of the financial statements were as follows:</span></p></div><div class="cln fn1" style="top:186.39pt;left:46.61pt;width:186.42pt;"><ix:nonNumeric contextRef="C_3_4" name="bus:NameEntityOfficer">Dr N P S Bajaj</ix:nonNumeric></div><div class="cln fn1" style="top:186.39pt;left:233.04pt;width:233pt;"></div><div class="cln fn1" style="top:197.4pt;left:46.61pt;width:186.42pt;"><ix:nonNumeric contextRef="C_3_6" name="bus:NameEntityOfficer">Dr N C Timberlake</ix:nonNumeric></div><div class="cln fn1" style="top:197.4pt;left:233.04pt;width:233pt;"></div><div class="cln" style="top:219pt;left:47pt;width:419pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.</span></p></div><div class="cln fn1" style="top:251.11pt;left:46.61pt;width:419.42pt;">This report was approved by the board of directors on 25 March 2020 and signed on behalf of the board by:</div><div class="cln fn1" style="top:295.14pt;left:46.61pt;width:419.42pt;"><ix:nonNumeric contextRef="C_3_6" name="direp:DirectorSigningDirectorsReport"></ix:nonNumeric>Dr N C Timberlake</div><div class="clb fn1" style="top:306.14pt;left:46.61pt;width:422.42pt;">Director</div></div><div class="portraitPage" style="height:727pt;width:516pt;"><div class="clb fn1" style="top:31.08pt;left:46.61pt;width:423.77pt;"></div><div class="clb fn2" style="top:40.75pt;left:46.61pt;width:423.77pt;"><ix:nonNumeric contextRef="C" name="bus:EntityCurrentLegalOrRegisteredName">NEUROMEDICA LIMITED</ix:nonNumeric></div><div class="clb fn2" style="top:54.9pt;left:46.61pt;width:423.77pt;"></div><div class="clb fn3" style="top:69.04pt;left:46.61pt;width:423.77pt;">ACCOUNTANTS' REPORT TO THE BOARD OF DIRECTORS ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF NEUROMEDICA LIMITED FOR THE YEAR ENDED 31 JULY 2019</div><div class="cln fn4" style="top:104.78pt;left:46.61pt;width:420.77pt;"></div><div class="cln fn0 sln" style="top:110.74pt;left:46.61pt;width:420.77pt;"></div><div class="cln fn0 sln" style="top:695.49pt;left:46.61pt;width:420.77pt;"></div><div class="ccn fn5" style="top:701.96pt;left:46.61pt;width:420.77pt;">- 2 -</div><div class="cln" style="top:124pt;left:47pt;width:419pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Neuromedica Limited for the year ended 31 July 2019 which comprise, the statement of financial position, the statement of changes in equity and the related notes from the company’s accounting records and from information and explanations you have given us.</span></p><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">&#160;</span></p><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at http://www.icaew.com/en/members/regulations-standards-and-guidance</span><span class="fn1">.</span></p></div><div class="cln" style="top:214pt;left:47pt;width:419pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><ix:nonNumeric contextRef="C" name="accrep:AccountantsReportOnFinancialStatements" continuedAt="C_BE_0"><span class="fn1">This report is made solely to the Board of Directors of Neuromedica Limited, as a body, in accordance with the terms of our engagement letter dated 25 February 2020. Our work has been undertaken solely to prepare for your approval the financial statements of Neuromedica Limited</span></ix:nonNumeric><span class="fn1"> </span><ix:continuation id="C_BE_0" continuedAt="C_BE_1"><span class="fn1">and state those matters that we have agreed to state to the Board of Directors of Neuromedica Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Neuromedica Limited and its Board of Directors as a body, for</span></ix:continuation><span class="fn1"> </span><ix:continuation id="C_BE_1"><span class="fn1">our work or for this report.</span></ix:continuation></p></div><div class="cln" style="top:284pt;left:47pt;width:419pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">It is your duty to ensure that Neuromedica Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets,</span><span class="fn1"> </span><span class="fn1">liabilities, financial position and profit</span><span class="fn1"> </span><span class="fn1">of Neuromedica Limited. You consider that Neuromedica Limited is exempt from the statutory audit</span><span class="fn1"> </span><span class="fn1">requirement for the year.</span></p></div><div class="cln" style="top:335pt;left:47pt;width:419pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">We have not been instructed to carry out an audit or a review of the financial statements of Neuromedica Limited. For this reason, we have not verified the accuracy or completeness of the</span><span class="fn1"> </span><span class="fn1">accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.</span></p></div><div class="clb fn1" style="top:429.79pt;left:46.61pt;width:421.87pt;">Higson &amp; Co.</div><div class="clb fn1" style="top:440.8pt;left:46.61pt;width:421.87pt;">Chartered Accountants</div><div class="clb fn1" style="top:462.81pt;left:46.61pt;width:421.87pt;">White House</div><div class="clb fn1" style="top:473.82pt;left:46.61pt;width:421.87pt;">Wollaton Street</div><div class="clb fn1" style="top:484.83pt;left:46.61pt;width:421.87pt;">Nottingham</div><div class="clb fn1" style="top:495.83pt;left:46.61pt;width:421.87pt;">NG1 5GF</div><div class="cln fn1" style="top:517.07pt;left:46.61pt;width:418.87pt;"><ix:nonNumeric contextRef="B" format="ixt:datelonguk" name="aurep:DateAuditorsReport">25 March 2020</ix:nonNumeric></div></div><div class="portraitPage" style="height:727pt;width:516pt;"><div class="clb fn1" style="top:31.08pt;left:46.61pt;width:423.77pt;"></div><div class="clb fn2" style="top:40.75pt;left:46.61pt;width:423.77pt;"><ix:nonNumeric contextRef="C" name="bus:EntityCurrentLegalOrRegisteredName">NEUROMEDICA LIMITED</ix:nonNumeric></div><div class="clb fn2" style="top:54.9pt;left:46.61pt;width:423.77pt;"></div><div class="clb fn3" style="top:69.04pt;left:46.61pt;width:423.77pt;">STATEMENT OF FINANCIAL POSITION </div><div class="cln fn4" style="top:80.95pt;left:46.61pt;width:420.77pt;"></div><div class="clbi fn3" style="top:86.91pt;left:46.61pt;width:423.77pt;"><div style="display:inline">AS AT 31 JULY 2019<div style="display:none"><ix:nonNumeric contextRef="B" format="ixt:datelonguk" name="bus:BalanceSheetDate">31 July 2019</ix:nonNumeric></div></div></div><div class="clb fn1" style="top:98.82pt;left:46.61pt;width:423.77pt;"></div><div class="cln fn0 sln" style="top:108.5pt;left:46.61pt;width:420.77pt;"></div><div class="cln fn0 sln" style="top:695.49pt;left:46.61pt;width:420.77pt;"></div><div class="ccn fn5" style="top:701.96pt;left:46.61pt;width:420.77pt;">- 3 -</div><div class="clb fn1" style="top:122.11pt;left:297.71pt;width:59.56pt;">2019</div><div class="clb fn1" style="top:122.11pt;left:410.83pt;width:59.55pt;">2018</div><div class="ccb fn1" style="top:133.12pt;left:206.98pt;width:37.17pt;">Notes</div><div class="crb fn1" style="top:133.12pt;left:238.15pt;width:59.56pt;">£</div><div class="crb fn1" style="top:133.12pt;left:294.71pt;width:59.56pt;">£</div><div class="crb fn1" style="top:133.12pt;left:351.27pt;width:59.55pt;">£</div><div class="crb fn1" style="top:133.12pt;left:407.83pt;width:59.55pt;">£</div><div class="cln fn6" style="top:133.12pt;left:468.03pt;width:0.65pt;"></div><div class="clb fn1" style="top:155.13pt;left:46.61pt;width:367.21pt;">Fixed assets</div><div class="cln fn1" style="top:166.14pt;left:46.61pt;width:160.36pt;">Tangible assets</div><div class="ccb fn1" style="top:166.14pt;left:206.98pt;width:37.17pt;">3</div><div class="crn fn1" style="top:166.14pt;left:297.71pt;width:56.56pt;"><ix:nonFraction contextRef="B" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:PropertyPlantEquipment">3,647</ix:nonFraction></div><div class="crn fn1" style="top:166.14pt;left:410.83pt;width:56.55pt;"><ix:nonFraction contextRef="E" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:PropertyPlantEquipment">2,887</ix:nonFraction></div><div class="clb fn1" style="top:188.15pt;left:46.61pt;width:197.53pt;">Current assets</div><div class="cln fn1" style="top:199.16pt;left:46.61pt;width:160.36pt;">Debtors</div><div class="ccb fn1" style="top:199.16pt;left:206.98pt;width:37.17pt;"></div><div class="crn fn1" style="top:199.16pt;left:241.15pt;width:56.56pt;"><ix:nonFraction contextRef="B" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:Debtors">1,438,820</ix:nonFraction></div><div class="crn fn1" style="top:199.16pt;left:354.27pt;width:56.55pt;"><ix:nonFraction contextRef="E" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:Debtors">1,562,947</ix:nonFraction></div><div class="cln fn1" style="top:210.16pt;left:46.61pt;width:160.36pt;">Cash at bank and in hand</div><div class="crn fn1" style="top:210.16pt;left:241.15pt;width:56.56pt;"><ix:nonFraction contextRef="B" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:CashBankOnHand">1,055,084</ix:nonFraction></div><div class="crn fn1" style="top:210.16pt;left:354.27pt;width:56.55pt;"><ix:nonFraction contextRef="E" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:CashBankOnHand">637,165</ix:nonFraction></div><div class="cln fn0 sln" style="top:226.01pt;left:260.26pt;width:37.45pt;"></div><div class="cln fn0 sln" style="top:226.01pt;left:373.38pt;width:37.45pt;"></div><div class="crn fn1" style="top:232.17pt;left:241.15pt;width:56.56pt;"><ix:nonFraction contextRef="B" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:CurrentAssets">2,493,904</ix:nonFraction></div><div class="crn fn1" style="top:232.17pt;left:354.27pt;width:56.55pt;"><ix:nonFraction contextRef="E" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:CurrentAssets">2,200,112</ix:nonFraction></div><div class="clb fn1" style="top:243.18pt;left:46.61pt;width:163.36pt;">Creditors: amounts falling due within one year</div><div class="ccb fn1" style="top:252.86pt;left:206.98pt;width:37.17pt;"></div><div class="crn fn1" style="top:252.86pt;left:243.95pt;width:56.56pt;">(<ix:nonFraction contextRef="B_F_AE" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:Creditors">170,046</ix:nonFraction>)</div><div class="crn fn1" style="top:252.86pt;left:357.07pt;width:56.55pt;">(<ix:nonFraction contextRef="E_F_AE" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:Creditors">204,559</ix:nonFraction>)</div><div class="cln fn0 sln" style="top:268.7pt;left:260.26pt;width:37.45pt;"></div><div class="cln fn0 sln" style="top:268.7pt;left:373.38pt;width:37.45pt;"></div><div class="clb fn1" style="top:274.87pt;left:46.61pt;width:254.09pt;">Net current assets</div><div class="crn fn1" style="top:274.87pt;left:297.71pt;width:56.56pt;"><ix:nonFraction contextRef="B" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:NetCurrentAssetsLiabilities">2,323,858</ix:nonFraction></div><div class="crn fn1" style="top:274.87pt;left:410.83pt;width:56.55pt;"><ix:nonFraction contextRef="E" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:NetCurrentAssetsLiabilities">1,995,553</ix:nonFraction></div><div class="cln fn0 sln" style="top:290.71pt;left:316.82pt;width:37.45pt;"></div><div class="cln fn0 sln" style="top:290.71pt;left:429.94pt;width:37.45pt;"></div><div class="clb fn1" style="top:296.88pt;left:46.61pt;width:197.53pt;">Total assets less current liabilities</div><div class="crn fn1" style="top:296.88pt;left:297.71pt;width:56.56pt;"><ix:nonFraction contextRef="B" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:TotalAssetsLessCurrentLiabilities">2,327,505</ix:nonFraction></div><div class="crn fn1" style="top:296.88pt;left:410.83pt;width:56.55pt;"><ix:nonFraction contextRef="E" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:TotalAssetsLessCurrentLiabilities">1,998,440</ix:nonFraction></div><div class="clb fn1" style="top:318.9pt;left:46.61pt;width:163.36pt;">Provisions for liabilities</div><div class="ccb fn1" style="top:318.9pt;left:206.98pt;width:37.17pt;"></div><div class="crn fn1" style="top:318.9pt;left:300.51pt;width:56.56pt;">(<ix:nonFraction contextRef="B" decimals="0" scale="0" unitRef="GBP" name="core:ProvisionsForLiabilitiesBalanceSheetSubtotal">693</ix:nonFraction>)</div><div class="crn fn1" style="top:318.9pt;left:413.63pt;width:56.55pt;">(<ix:nonFraction contextRef="E" decimals="0" scale="0" unitRef="GBP" name="core:ProvisionsForLiabilitiesBalanceSheetSubtotal">549</ix:nonFraction>)</div><div class="cln fn0 sln" style="top:334.74pt;left:316.82pt;width:37.45pt;"></div><div class="cln fn0 sln" style="top:334.74pt;left:429.94pt;width:37.45pt;"></div><div class="clb fn1" style="top:340.91pt;left:46.61pt;width:197.53pt;">Net assets</div><div class="crn fn1" style="top:340.91pt;left:297.71pt;width:56.56pt;"><ix:nonFraction contextRef="B" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:NetAssetsLiabilities">2,326,812</ix:nonFraction></div><div class="crn fn1" style="top:340.91pt;left:410.83pt;width:56.55pt;"><ix:nonFraction contextRef="E" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:NetAssetsLiabilities">1,997,891</ix:nonFraction></div><div class="cln fn0 dln" style="top:356.75pt;left:316.82pt;width:37.45pt;"></div><div class="cln fn0 dln" style="top:356.75pt;left:429.94pt;width:37.45pt;"></div><div class="clb fn1" style="top:373.93pt;left:46.61pt;width:163.36pt;">Capital and reserves</div><div class="cln fn1" style="top:384.93pt;left:46.61pt;width:160.36pt;">Called up share capital</div><div class="ccb fn1" style="top:384.93pt;left:206.98pt;width:37.17pt;">4</div><div class="crn fn1" style="top:384.93pt;left:297.71pt;width:56.56pt;"><ix:nonFraction contextRef="B_AF_AG" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:Equity">1,000</ix:nonFraction></div><div class="crn fn1" style="top:384.93pt;left:410.83pt;width:56.55pt;"><ix:nonFraction contextRef="E_AF_AG" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:Equity">1,000</ix:nonFraction></div><div class="cln fn1" style="top:395.94pt;left:46.61pt;width:160.36pt;">Profit and loss reserves</div><div class="ccb fn1" style="top:395.94pt;left:206.98pt;width:37.17pt;"></div><div class="crn fn1" style="top:395.94pt;left:297.71pt;width:56.56pt;"><ix:nonFraction contextRef="B_AF_AH" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:Equity">2,325,812</ix:nonFraction></div><div class="crn fn1" style="top:395.94pt;left:410.83pt;width:56.55pt;"><ix:nonFraction contextRef="E_AF_AH" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:Equity">1,996,891</ix:nonFraction></div><div class="cln fn0 sln" style="top:411.78pt;left:316.82pt;width:37.45pt;"></div><div class="cln fn0 sln" style="top:411.78pt;left:429.94pt;width:37.45pt;"></div><div class="clb fn1" style="top:417.95pt;left:46.61pt;width:197.53pt;">Total equity</div><div class="crn fn1" style="top:417.95pt;left:297.71pt;width:56.56pt;"><ix:nonFraction contextRef="B" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:Equity">2,326,812</ix:nonFraction></div><div class="crn fn1" style="top:417.95pt;left:410.83pt;width:56.55pt;"><ix:nonFraction contextRef="E" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:Equity">1,997,891</ix:nonFraction></div><div class="cln fn0 dln" style="top:433.8pt;left:316.82pt;width:37.45pt;"></div><div class="cln fn0 dln" style="top:433.8pt;left:429.94pt;width:37.45pt;"></div><div class="cln" style="top:451pt;left:47pt;width:421pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><ix:nonNumeric contextRef="C" name="direp:StatementThatMembersHaveAgreedToPreparationAbridgedAccountsUnderSection444CompaniesAct2006" continuedAt="C_BF_0"><span class="fn1">In accordance with section 444 of the Companies Act 2006 all</span></ix:nonNumeric><span class="fn1"> </span><ix:continuation id="C_BF_0" continuedAt="C_BF_1"><span class="fn1">of </span></ix:continuation><span class="fn1"></span><ix:continuation id="C_BF_1" continuedAt="C_BF_2"><span class="fn1">the members of the company have consented to the </span></ix:continuation><span class="fn1"></span><ix:continuation id="C_BF_2"><span class="fn1">preparation of abridged financial statements pursuant to paragraph 1A of Schedule 1 to the Small Companies and Groups (Accounts and Directors’ Report) Regulations (S.I. 2008/409)(b).</span></ix:continuation></p></div><div class="cln" style="top:492pt;left:47pt;width:421pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><ix:nonNumeric contextRef="C" name="direp:EntityHasTakenExemptionUnderCompaniesActInNotPublishingItsOwnProfitLossAccountTruefalse"><span class="fn1"><ix:exclude>The directors of the company have elected not to include a copy of the income statement within the financial statements.</ix:exclude><span style="display:none">true</span></span></ix:nonNumeric></p></div><div class="cln" style="top:524pt;left:47pt;width:421pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><ix:nonNumeric contextRef="C" name="direp:StatementThatCompanyEntitledToExemptionFromAuditUnderSection477CompaniesAct2006RelatingToSmallCompanies"><span class="fn1">For the financial year ended 31 July 2019 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.</span></ix:nonNumeric></p></div><div class="cln" style="top:556pt;left:47pt;width:421pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><ix:nonNumeric contextRef="C" name="direp:StatementThatDirectorsAcknowledgeTheirResponsibilitiesUnderCompaniesAct"><span class="fn1">The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.</span></ix:nonNumeric></p></div><div class="cln" style="top:587pt;left:47pt;width:421pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><ix:nonNumeric contextRef="C" name="direp:StatementThatMembersHaveNotRequiredCompanyToObtainAnAudit" continuedAt="C_BG_0"><span class="fn1">T</span></ix:nonNumeric><span class="fn1"></span><ix:continuation id="C_BG_0" continuedAt="C_BG_1"><span class="fn1">he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476</span></ix:continuation><span class="fn1"></span><ix:continuation id="C_BG_1"><span class="fn1">.</span></ix:continuation></p></div><div class="cln" style="top:619pt;left:47pt;width:421pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><ix:nonNumeric contextRef="C" name="direp:StatementThatAccountsHaveBeenPreparedInAccordanceWithProvisionsSmallCompaniesRegime"><span class="fn1">These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.</span></ix:nonNumeric></p></div></div><div class="portraitPage" style="height:727pt;width:516pt;"><div class="clb fn1" style="top:31.08pt;left:46.61pt;width:423.77pt;"></div><div class="clb fn2" style="top:40.75pt;left:46.61pt;width:423.77pt;"><ix:nonNumeric contextRef="C" name="bus:EntityCurrentLegalOrRegisteredName">NEUROMEDICA LIMITED</ix:nonNumeric></div><div class="clb fn2" style="top:54.9pt;left:46.61pt;width:423.77pt;"></div><div class="clb fn3" style="top:69.04pt;left:46.61pt;width:423.77pt;">STATEMENT OF FINANCIAL POSITION (CONTINUED)</div><div class="cln fn4" style="top:80.95pt;left:46.61pt;width:420.77pt;"></div><div class="clbi fn3" style="top:86.91pt;left:46.61pt;width:423.77pt;"><div style="display:inline">AS AT 31 JULY 2019<div style="display:none"><ix:nonNumeric contextRef="B" format="ixt:datelonguk" name="bus:BalanceSheetDate">31 July 2019</ix:nonNumeric></div></div></div><div class="clb fn1" style="top:98.82pt;left:46.61pt;width:423.77pt;"></div><div class="cln fn0 sln" style="top:108.5pt;left:46.61pt;width:420.77pt;"></div><div class="cln fn0 sln" style="top:695.49pt;left:46.61pt;width:420.77pt;"></div><div class="ccn fn5" style="top:701.96pt;left:46.61pt;width:420.77pt;">- 4 -</div><div class="cjn fn1" style="top:122.11pt;left:46.61pt;width:420.77pt;">The financial statements were approved by the board of directors and authorised for issue on <ix:nonNumeric contextRef="B" format="ixt:datelonguk" name="core:DateAuthorisationFinancialStatementsForIssue">25 March 2020</ix:nonNumeric> and are signed on its behalf by:</div><div class="cln fn1" style="top:175.82pt;left:46.61pt;width:420.77pt;"><ix:nonNumeric contextRef="C_3_4" name="core:DirectorSigningFinancialStatements"></ix:nonNumeric>Dr N P S Bajaj</div><div class="clb fn1" style="top:186.82pt;left:46.61pt;width:423.77pt;">Director</div><div class="clb fn1" style="top:208.83pt;left:46.61pt;width:423.77pt;">Company Registration No. 07316989</div></div><div class="portraitPage" style="height:727pt;width:516pt;"><div class="clb fn1" style="top:31.08pt;left:46.61pt;width:423.77pt;"></div><div class="clb fn2" style="top:40.75pt;left:46.61pt;width:423.77pt;"><ix:nonNumeric contextRef="C" name="bus:EntityCurrentLegalOrRegisteredName">NEUROMEDICA LIMITED</ix:nonNumeric></div><div class="clb fn2" style="top:54.9pt;left:46.61pt;width:423.77pt;"></div><div class="clb fn3" style="top:69.04pt;left:46.61pt;width:423.77pt;">STATEMENT OF CHANGES IN EQUITY </div><div class="cln fn4" style="top:80.95pt;left:46.61pt;width:420.77pt;"></div><div class="clbi fn3" style="top:86.91pt;left:46.61pt;width:423.77pt;">FOR THE YEAR ENDED 31 JULY 2019</div><div class="clb fn1" style="top:98.82pt;left:46.61pt;width:423.77pt;"></div><div class="cln fn0 sln" style="top:108.5pt;left:46.61pt;width:420.77pt;"></div><div class="cln fn0 sln" style="top:695.49pt;left:46.61pt;width:420.77pt;"></div><div class="ccn fn5" style="top:701.96pt;left:46.61pt;width:420.77pt;">- 5 -</div><div class="crb fn1" style="top:122.11pt;left:315.23pt;width:52.72pt;">Share capital</div><div class="crb fn1" style="top:122.11pt;left:364.95pt;width:52.72pt;">Profit and loss reserves</div><div class="crb fn1" style="top:122.11pt;left:414.68pt;width:52.71pt;">Total</div><div class="ccb fn1" style="top:152.48pt;left:285.92pt;width:35.31pt;">Notes</div><div class="crb fn1" style="top:152.48pt;left:315.23pt;width:52.72pt;">£</div><div class="crb fn1" style="top:152.48pt;left:364.95pt;width:52.72pt;">£</div><div class="crb fn1" style="top:152.48pt;left:414.68pt;width:52.71pt;">£</div><div class="cln fn6" style="top:152.48pt;left:468.03pt;width:0.65pt;"></div><div class="clb fn1" style="top:174.49pt;left:46.61pt;width:242.3pt;">Balance at 1 August 2017</div><div class="crn fn1" style="top:174.49pt;left:318.23pt;width:49.72pt;"><ix:nonFraction contextRef="D_AF_AG" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:Equity">1,000</ix:nonFraction></div><div class="crn fn1" style="top:174.49pt;left:367.95pt;width:49.72pt;"><ix:nonFraction contextRef="D_AF_AH" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:Equity">1,388,025</ix:nonFraction></div><div class="crn fn1" style="top:174.49pt;left:417.68pt;width:49.71pt;"><ix:nonFraction contextRef="D" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:Equity">1,389,025</ix:nonFraction></div><div class="clb fn1" style="top:196.5pt;left:46.61pt;width:242.3pt;">Year ended 31 July 2018:</div><div class="cln fn1" style="top:207.51pt;left:46.61pt;width:239.3pt;">Profit and total comprehensive income for the year</div><div class="crn fn1" style="top:207.51pt;left:318.23pt;width:49.72pt;">-</div><div class="crn fn1" style="top:207.51pt;left:367.95pt;width:49.72pt;"><ix:nonFraction contextRef="F_AF_AH" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:ProfitLoss">693,866</ix:nonFraction></div><div class="crn fn1" style="top:207.51pt;left:417.68pt;width:49.71pt;"><ix:nonFraction contextRef="F" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:ProfitLoss">693,866</ix:nonFraction></div><div class="cln fn1" style="top:218.51pt;left:46.61pt;width:239.3pt;">Dividends</div><div class="ccb fn1" style="top:218.51pt;left:285.92pt;width:35.31pt;"></div><div class="crn fn1" style="top:218.51pt;left:318.23pt;width:49.72pt;">-</div><div class="crn fn1" style="top:218.51pt;left:370.76pt;width:49.72pt;">(<ix:nonFraction contextRef="F_AF_AH" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:DividendsPaid">85,000</ix:nonFraction>)</div><div class="crn fn1" style="top:218.51pt;left:420.48pt;width:49.71pt;">(<ix:nonFraction contextRef="F_AF_AH" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:DividendsPaid">85,000</ix:nonFraction>)</div><div class="cln fn0 sln" style="top:234.36pt;left:330.51pt;width:37.45pt;"></div><div class="cln fn0 sln" style="top:234.36pt;left:380.23pt;width:37.45pt;"></div><div class="cln fn0 sln" style="top:234.36pt;left:429.94pt;width:37.45pt;"></div><div class="clb fn1" style="top:240.53pt;left:46.61pt;width:242.3pt;">Balance at 31 July 2018</div><div class="crn fn1" style="top:240.53pt;left:318.23pt;width:49.72pt;"><ix:nonFraction contextRef="E_AF_AG" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:Equity">1,000</ix:nonFraction></div><div class="crn fn1" style="top:240.53pt;left:367.95pt;width:49.72pt;"><ix:nonFraction contextRef="E_AF_AH" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:Equity">1,996,891</ix:nonFraction></div><div class="crn fn1" style="top:240.53pt;left:417.68pt;width:49.71pt;"><ix:nonFraction contextRef="E" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:Equity">1,997,891</ix:nonFraction></div><div class="clb fn1" style="top:262.54pt;left:46.61pt;width:242.3pt;">Year ended 31 July 2019:</div><div class="cln fn1" style="top:273.54pt;left:46.61pt;width:239.3pt;">Profit and total comprehensive income for the year</div><div class="crn fn1" style="top:273.54pt;left:318.23pt;width:49.72pt;">-</div><div class="crn fn1" style="top:273.54pt;left:367.95pt;width:49.72pt;"><ix:nonFraction contextRef="C_AF_AH" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:ProfitLoss">398,921</ix:nonFraction></div><div class="crn fn1" style="top:273.54pt;left:417.68pt;width:49.71pt;"><ix:nonFraction contextRef="C" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:ProfitLoss">398,921</ix:nonFraction></div><div class="cln fn1" style="top:284.55pt;left:46.61pt;width:239.3pt;">Dividends</div><div class="ccb fn1" style="top:284.55pt;left:285.92pt;width:35.31pt;"></div><div class="crn fn1" style="top:284.55pt;left:318.23pt;width:49.72pt;">-</div><div class="crn fn1" style="top:284.55pt;left:370.76pt;width:49.72pt;">(<ix:nonFraction contextRef="C" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:DividendsPaid">70,000</ix:nonFraction>)</div><div class="crn fn1" style="top:284.55pt;left:420.48pt;width:49.71pt;">(<ix:nonFraction contextRef="C" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:DividendsPaid">70,000</ix:nonFraction>)</div><div class="cln fn0 sln" style="top:300.39pt;left:330.51pt;width:37.45pt;"></div><div class="cln fn0 sln" style="top:300.39pt;left:380.23pt;width:37.45pt;"></div><div class="cln fn0 sln" style="top:300.39pt;left:429.94pt;width:37.45pt;"></div><div class="clb fn1" style="top:306.56pt;left:46.61pt;width:274.62pt;">Balance at 31 July 2019</div><div class="crn fn1" style="top:306.56pt;left:318.23pt;width:49.72pt;"><ix:nonFraction contextRef="B_AF_AG" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:Equity">1,000</ix:nonFraction></div><div class="crn fn1" style="top:306.56pt;left:367.95pt;width:49.72pt;"><ix:nonFraction contextRef="B_AF_AH" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:Equity">2,325,812</ix:nonFraction></div><div class="crn fn1" style="top:306.56pt;left:417.68pt;width:49.71pt;"><ix:nonFraction contextRef="B" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:Equity">2,326,812</ix:nonFraction></div><div class="cln fn0 dln" style="top:322.41pt;left:330.51pt;width:37.45pt;"></div><div class="cln fn0 dln" style="top:322.41pt;left:380.23pt;width:37.45pt;"></div><div class="cln fn0 dln" style="top:322.41pt;left:429.94pt;width:37.45pt;"></div></div><div class="portraitPage" style="height:727pt;width:516pt;"><div class="clb fn1" style="top:31.08pt;left:46.61pt;width:423.77pt;"></div><div class="clb fn2" style="top:40.75pt;left:46.61pt;width:423.77pt;"><ix:nonNumeric contextRef="C" name="bus:EntityCurrentLegalOrRegisteredName">NEUROMEDICA LIMITED</ix:nonNumeric></div><div class="clb fn2" style="top:54.9pt;left:46.61pt;width:423.77pt;"></div><div class="clb fn3" style="top:69.04pt;left:46.61pt;width:423.77pt;">NOTES TO THE FINANCIAL STATEMENTS </div><div class="cln fn4" style="top:80.95pt;left:46.61pt;width:420.77pt;"></div><div class="clbi fn3" style="top:86.91pt;left:46.61pt;width:423.77pt;">FOR THE YEAR ENDED 31 JULY 2019</div><div class="clb fn1" style="top:98.82pt;left:46.61pt;width:423.77pt;"></div><div class="cln fn0 sln" style="top:108.5pt;left:46.61pt;width:420.77pt;"></div><div class="cln fn0 sln" style="top:695.49pt;left:46.61pt;width:420.77pt;"></div><div class="ccn fn5" style="top:701.96pt;left:46.61pt;width:420.77pt;">- 6 -</div><div class="clb fn1" style="top:122.11pt;left:46.61pt;width:24.12pt;">1</div><div class="clb fn1" style="top:122.11pt;left:67.73pt;width:401.41pt;">Accounting policies</div><div class="cln fn6" style="top:122.11pt;left:466.79pt;width:0.65pt;"></div><div class="clb fn1" style="top:144.12pt;left:67.73pt;width:401.41pt;">Company information</div><div class="cln" style="top:155pt;left:68pt;width:398pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">Neuromedica Limited is a</span><span class="fn1"> private </span><span class="fn1">company</span><span class="fn1"> limited by shares</span><span class="fn1"> incorporated in England and Wales.</span><span class="fn1"> </span><span class="fn1">The registered office is</span><span class="fn1"> White House, Wollaton Street, Nottingham, NG1 5GF. The company&apos;s trading address is 3 Grosvenor Avenue, Mapperley, Nottingham, NG3 5DX.</span></p></div><div class="clb fn1" style="top:196.51pt;left:46.61pt;width:24.12pt;">1.1</div><div class="clb fn1" style="top:196.51pt;left:67.73pt;width:401.41pt;">Accounting convention</div><div class="cln" style="top:207pt;left:68pt;width:398pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><ix:nonNumeric contextRef="C" name="core:StatementComplianceWithApplicableReportingFramework"><span class="fn1">These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.</span></ix:nonNumeric></p></div><div class="cln" style="top:268pt;left:68pt;width:398pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">The financial statements are prepared in</span><span class="fn1"> sterling</span><span class="fn1">, which is the functional currency of the company. </span><span class="fn1">Monetary a</span><span class="fn1">mounts </span><span class="fn1">in these financial statements are </span><span class="fn1">rounded to the nearest £.</span></p></div><div class="clb fn1" style="top:299.51pt;left:46.61pt;width:24.12pt;">1.2</div><div class="clb fn1" style="top:299.51pt;left:67.73pt;width:401.41pt;">Turnover</div><div class="cln" style="top:310pt;left:68pt;width:398pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><ix:nonNumeric contextRef="C" name="core:RevenueRecognitionPolicy" continuedAt="C_BH_0"><span class="fn1">Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business</span></ix:nonNumeric><span class="fn1"></span><ix:continuation id="C_BH_0" continuedAt="C_BH_1"><span class="fn1">, and</span></ix:continuation><span class="fn1"></span><ix:continuation id="C_BH_1" continuedAt="C_BH_2"><span class="fn1"> is shown net of VAT and other sales related taxes</span></ix:continuation><span class="fn1"></span><ix:continuation id="C_BH_2" continuedAt="C_BH_3"><span class="fn1">. </span></ix:continuation><span class="fn1"></span><ix:continuation id="C_BH_3" continuedAt="C_BH_4"><span class="fn1">The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.</span></ix:continuation></p><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">&#160;</span></p><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><ix:continuation id="C_BH_4" continuedAt="C_BH_5"><span class="fn1">When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.</span></ix:continuation></p></div><div class="cln" style="top:390pt;left:68pt;width:398pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><ix:continuation id="C_BH_5" continuedAt="C_BH_6"><span class="fn1">Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs.  Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that </span></ix:continuation><span class="fn1"></span><ix:continuation id="C_BH_6" continuedAt="C_BH_7"><span class="fn1">it is probable will be</span></ix:continuation><span class="fn1"></span><ix:continuation id="C_BH_7" continuedAt="C_BH_8"><span class="fn1"> recover</span></ix:continuation><span class="fn1"></span><ix:continuation id="C_BH_8" continuedAt="C_BH_9"><span class="fn1">ed</span></ix:continuation><span class="fn1"></span><ix:continuation id="C_BH_9"><span class="fn1">.</span></ix:continuation></p></div><div class="clb fn1" style="top:460.58pt;left:46.61pt;width:24.12pt;">1.3</div><div class="clb fn1" style="top:460.58pt;left:67.73pt;width:401.41pt;">Tangible fixed assets</div><div class="cln" style="top:471pt;left:68pt;width:398pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><ix:nonNumeric contextRef="C" name="core:DescriptionMeasurementBasisForPropertyPlantEquipment" continuedAt="C_BI_0"><span class="fn1">Tangible fixed assets </span></ix:nonNumeric><span class="fn1"></span><ix:continuation id="C_BI_0"><span class="fn1">are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.</span></ix:continuation></p></div><div class="cln" style="top:503pt;left:68pt;width:398pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Justify;"><ix:nonNumeric contextRef="C" name="core:DescriptionDepreciationMethodForPropertyPlantEquipment"><span class="fn1">Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:</span></ix:nonNumeric></p></div><div class="cln fn1" style="top:534.54pt;left:67.73pt;width:172.16pt;">Fixtures and fittings</div><div class="cln fn1" style="top:534.54pt;left:239.9pt;width:227.49pt;"><ix:nonNumeric contextRef="C_7_AP" name="core:DescriptionDepreciationMethodForPropertyPlantEquipment">25% reducing balance</ix:nonNumeric></div><div class="cln" style="top:556pt;left:68pt;width:398pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and </span><span class="fn1">is credited or charged to profit or loss</span><span class="fn1">.</span></p></div></div><div class="portraitPage" style="height:727pt;width:516pt;"><div class="clb fn1" style="top:31.08pt;left:46.61pt;width:423.77pt;"></div><div class="clb fn2" style="top:40.75pt;left:46.61pt;width:423.77pt;"><ix:nonNumeric contextRef="C" name="bus:EntityCurrentLegalOrRegisteredName">NEUROMEDICA LIMITED</ix:nonNumeric></div><div class="clb fn2" style="top:54.9pt;left:46.61pt;width:423.77pt;"></div><div class="clb fn3" style="top:69.04pt;left:46.61pt;width:423.77pt;">NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)</div><div class="cln fn4" style="top:80.95pt;left:46.61pt;width:420.77pt;"></div><div class="clbi fn3" style="top:86.91pt;left:46.61pt;width:423.77pt;">FOR THE YEAR ENDED 31 JULY 2019</div><div class="clb fn1" style="top:98.82pt;left:46.61pt;width:423.77pt;"></div><div class="cln fn0 sln" style="top:108.5pt;left:46.61pt;width:420.77pt;"></div><div class="clb fn1" style="top:121.45pt;left:46.61pt;width:24.12pt;">1</div><div class="clb fn1" style="top:121.45pt;left:67.73pt;width:401.41pt;">Accounting policies</div><div class="crb fn1" style="top:121.45pt;left:378.06pt;width:89.32pt;">(Continued)</div><div class="cln fn0 sln" style="top:695.49pt;left:46.61pt;width:420.77pt;"></div><div class="ccn fn5" style="top:701.96pt;left:46.61pt;width:420.77pt;">- 7 -</div><div class="clb fn1" style="top:144.12pt;left:46.61pt;width:24.12pt;">1.4</div><div class="clb fn1" style="top:144.12pt;left:67.73pt;width:401.41pt;">Impairment of fixed assets</div><div class="cln" style="top:155pt;left:68pt;width:398pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><ix:nonNumeric contextRef="C" name="core:ImpairmentNon-financialAssetsPolicy" continuedAt="C_BJ_0"><span class="fn1">A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.</span></ix:nonNumeric></p><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">&#160;</span></p><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><ix:continuation id="C_BJ_0"><span class="fn1">When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs.  The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.</span></ix:continuation></p></div><div class="clb fn1" style="top:254.36pt;left:46.61pt;width:24.12pt;">1.5</div><div class="clb fn1" style="top:254.36pt;left:67.73pt;width:401.41pt;">Financial instruments</div><div class="cln" style="top:265pt;left:68pt;width:398pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><ix:nonNumeric contextRef="C" name="core:FinancialInstrumentsClassificationPolicy" continuedAt="C_BK_0"><span class="fn1">The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments. </span></ix:nonNumeric></p><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">&#160;</span></p><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><ix:continuation id="C_BK_0" continuedAt="C_BK_1"><span class="fn1">Financial instruments are recognised in the company&apos;s statement of financial position when the company becomes party to the contractual provisions of the instrument.</span></ix:continuation></p><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">&#160;</span></p><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><ix:continuation id="C_BK_1" continuedAt="C_BK_2"><span class="fn1">Financial assets and liabilities are offset</span></ix:continuation><span class="fn1"></span><ix:continuation id="C_BK_2" continuedAt="C_BK_3"><span class="fn1">, with</span></ix:continuation><span class="fn1"></span><ix:continuation id="C_BK_3" continuedAt="C_BK_4"><span class="fn1"> the net amounts presented in the financial statements</span></ix:continuation><span class="fn1"></span><ix:continuation id="C_BK_4" continuedAt="C_BK_5"><span class="fn1">,</span></ix:continuation><span class="fn1"></span><ix:continuation id="C_BK_5"><span class="fn1"> when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.</span></ix:continuation></p></div><div class="clbi fn1" style="top:364.5pt;left:67.73pt;width:344.85pt;">Basic financial assets</div><div class="cln" style="top:375pt;left:68pt;width:398pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest</span><span class="fn1"> </span><span class="fn1">method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.</span><span class="fn1"> Financial assets classified as receivable within one year are not amortised.</span></p></div><div class="clbi fn1" style="top:435.8pt;left:67.73pt;width:401.41pt;">Classification of financial liabilities</div><div class="cln" style="top:447pt;left:68pt;width:398pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.</span></p></div><div class="clbi fn1" style="top:487.75pt;left:67.73pt;width:401.41pt;">Basic financial liabilities</div><div class="cln" style="top:499pt;left:68pt;width:398pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">Basic financial liabilities, including creditors, bank loans, loans from</span><span class="fn1"> </span><span class="fn1">fellow group companies and preference shares that are classified as debt, are</span><span class="fn1"> </span><span class="fn1">initially recognised at transaction price unless the arrangement constitutes a</span><span class="fn1"> </span><span class="fn1">financing transaction, where the debt instrument is measured at the present value of</span><span class="fn1"> </span><span class="fn1">the future </span><span class="fn1">paymen</span><span class="fn1">ts discounted at a market rate of interest.</span><span class="fn1"> Financial liabilities classified as payable within one year are not amortised.</span></p><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">&#160;</span></p><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">Debt instruments are subsequently carried at amortised cost, using the effective</span><span class="fn1"> </span><span class="fn1">interest rate method.</span></p><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">&#160;</span></p><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">Trade creditors</span><span class="fn1"> are obligations to pay for goods or services that have been acquired</span><span class="fn1"> </span><span class="fn1">in the ordinary course of business from suppliers. A</span><span class="fn1">m</span><span class="fn1">ounts payable are classified as</span><span class="fn1"> </span><span class="fn1">current liabilities if payment is due within one year or less. If not, they are presented</span><span class="fn1"> </span><span class="fn1">as non-current liabilities. Trade creditors are recognised initially at transaction price</span><span class="fn1"> </span><span class="fn1">and subsequently measured at amortised cost using the effective interest method.</span></p></div><div class="clb fn1" style="top:626.91pt;left:46.61pt;width:24.12pt;">1.6</div><div class="clb fn1" style="top:626.91pt;left:67.73pt;width:401.41pt;">Taxation</div><div class="cln" style="top:638pt;left:68pt;width:398pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Justify;"><ix:nonNumeric contextRef="C" name="core:TaxPolicy"><span class="fn1">The tax expense represents the sum of the tax currently payable and deferred tax.</span></ix:nonNumeric></p></div></div><div class="portraitPage" style="height:727pt;width:516pt;"><div class="clb fn1" style="top:31.08pt;left:46.61pt;width:423.77pt;"></div><div class="clb fn2" style="top:40.75pt;left:46.61pt;width:423.77pt;"><ix:nonNumeric contextRef="C" name="bus:EntityCurrentLegalOrRegisteredName">NEUROMEDICA LIMITED</ix:nonNumeric></div><div class="clb fn2" style="top:54.9pt;left:46.61pt;width:423.77pt;"></div><div class="clb fn3" style="top:69.04pt;left:46.61pt;width:423.77pt;">NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)</div><div class="cln fn4" style="top:80.95pt;left:46.61pt;width:420.77pt;"></div><div class="clbi fn3" style="top:86.91pt;left:46.61pt;width:423.77pt;">FOR THE YEAR ENDED 31 JULY 2019</div><div class="clb fn1" style="top:98.82pt;left:46.61pt;width:423.77pt;"></div><div class="cln fn0 sln" style="top:108.5pt;left:46.61pt;width:420.77pt;"></div><div class="clb fn1" style="top:121.45pt;left:46.61pt;width:24.12pt;">1</div><div class="clb fn1" style="top:121.45pt;left:67.73pt;width:401.41pt;">Accounting policies</div><div class="crb fn1" style="top:121.45pt;left:378.06pt;width:89.32pt;">(Continued)</div><div class="cln fn0 sln" style="top:695.49pt;left:46.61pt;width:420.77pt;"></div><div class="ccn fn5" style="top:701.96pt;left:46.61pt;width:420.77pt;">- 8 -</div><div class="clbi fn1" style="top:144.02pt;left:67.73pt;width:401.41pt;">Current tax</div><div class="cln" style="top:155pt;left:68pt;width:398pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><ix:nonNumeric contextRef="C" name="core:CurrentIncomeTaxPolicy" continuedAt="C_BL_0"><span class="fn1">The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The </span></ix:nonNumeric><span class="fn1"></span><ix:continuation id="C_BL_0" continuedAt="C_BL_1"><span class="fn1">company’s </span></ix:continuation><span class="fn1"></span><ix:continuation id="C_BL_1"><span class="fn1">liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.</span></ix:continuation></p></div><div class="clbi fn1" style="top:215.32pt;left:67.73pt;width:401.41pt;">Deferred tax</div><div class="cln" style="top:226pt;left:68pt;width:398pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><ix:nonNumeric contextRef="C" name="core:DeferredTaxPolicy" continuedAt="C_BM_0"><span class="fn1">Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.</span></ix:nonNumeric></p><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">&#160;</span></p><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><ix:continuation id="C_BM_0" continuedAt="C_BM_1"><span class="fn1">The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the income statement, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the </span></ix:continuation><span class="fn1"></span><ix:continuation id="C_BM_1" continuedAt="C_BM_2"><span class="fn1">company </span></ix:continuation><span class="fn1"></span><ix:continuation id="C_BM_2"><span class="fn1">has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.</span></ix:continuation></p></div><div class="clb fn1" style="top:373.85pt;left:46.61pt;width:24.12pt;">1.7</div><div class="clb fn1" style="top:373.85pt;left:67.73pt;width:401.41pt;">Employee benefits</div><div class="cln" style="top:385pt;left:68pt;width:398pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><ix:nonNumeric contextRef="C" name="core:EmployeeBenefitsPolicy" continuedAt="C_BN_0"><span class="fn1">The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.  </span></ix:nonNumeric></p><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">&#160;</span></p><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><ix:continuation id="C_BN_0" continuedAt="C_BN_1"><span class="fn1">The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.</span></ix:continuation></p><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">&#160;</span></p><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><ix:continuation id="C_BN_1"><span class="fn1">Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.</span></ix:continuation></p></div><div class="clb fn1" style="top:474.41pt;left:46.61pt;width:24.12pt;">1.8</div><div class="clb fn1" style="top:474.41pt;left:67.73pt;width:401.41pt;">Retirement benefits</div><div class="cln" style="top:485pt;left:68pt;width:398pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Justify;"><ix:nonNumeric contextRef="C" name="core:DefinedContributionPensionsPolicy"><span class="fn1">Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.</span></ix:nonNumeric></p></div><div class="clb fn1" style="top:507.21pt;left:46.61pt;width:24.12pt;">1.9</div><div class="clb fn1" style="top:507.21pt;left:67.73pt;width:401.41pt;">Leases</div><div class="cln" style="top:518pt;left:68pt;width:398pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><ix:nonNumeric contextRef="C" name="core:LessorOperatingLeasePolicy" continuedAt="C_BO_0"><span class="fn1">Rentals payable under operating leases, </span></ix:nonNumeric><span class="fn1"></span><ix:continuation id="C_BO_0" continuedAt="C_BO_1"><span class="fn1">including</span></ix:continuation><span class="fn1"></span><ix:continuation id="C_BO_1" continuedAt="C_BO_2"><span class="fn1"> any lease incentives received, are charged to </span></ix:continuation><span class="fn1"></span><ix:continuation id="C_BO_2" continuedAt="C_BO_3"><span class="fn1">profit or loss</span></ix:continuation><span class="fn1"></span><ix:continuation id="C_BO_3" continuedAt="C_BO_4"><span class="fn1"> on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease</span></ix:continuation><span class="fn1"></span><ix:continuation id="C_BO_4" continuedAt="C_BO_5"><span class="fn1">s</span></ix:continuation><span class="fn1"></span><ix:continuation id="C_BO_5"><span class="fn1"> asset are consumed.</span></ix:continuation><span class="fn1"> </span></p></div><div class="clb fn1" style="top:569.06pt;left:46.61pt;width:24.12pt;">2</div><div class="clb fn1" style="top:569.06pt;left:67.73pt;width:402.65pt;">Employees</div><div class="cln" style="top:591pt;left:68pt;width:400pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">The average monthly number of persons (including directors) employed by the company during the year was 2 (2018 - 2).</span></p></div></div><div class="portraitPage" style="height:727pt;width:516pt;"><div class="clb fn1" style="top:31.08pt;left:46.61pt;width:423.77pt;"></div><div class="clb fn2" style="top:40.75pt;left:46.61pt;width:423.77pt;"><ix:nonNumeric contextRef="C" name="bus:EntityCurrentLegalOrRegisteredName">NEUROMEDICA LIMITED</ix:nonNumeric></div><div class="clb fn2" style="top:54.9pt;left:46.61pt;width:423.77pt;"></div><div class="clb fn3" style="top:69.04pt;left:46.61pt;width:423.77pt;">NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)</div><div class="cln fn4" style="top:80.95pt;left:46.61pt;width:420.77pt;"></div><div class="clbi fn3" style="top:86.91pt;left:46.61pt;width:423.77pt;">FOR THE YEAR ENDED 31 JULY 2019</div><div class="clb fn1" style="top:98.82pt;left:46.61pt;width:423.77pt;"></div><div class="cln fn0 sln" style="top:108.5pt;left:46.61pt;width:420.77pt;"></div><div class="cln fn0 sln" style="top:695.49pt;left:46.61pt;width:420.77pt;"></div><div class="ccn fn5" style="top:701.96pt;left:46.61pt;width:420.77pt;">- 9 -</div><div class="clb fn1" style="top:122.11pt;left:46.61pt;width:24.12pt;">3</div><div class="clb fn1" style="top:122.11pt;left:67.73pt;width:402.65pt;">Tangible fixed assets</div><div class="cln fn6" style="top:122.11pt;left:468.03pt;width:0.65pt;"></div><div class="crb fn1" style="top:133.12pt;left:414.68pt;width:52.71pt;">Total</div><div class="crb fn1" style="top:144.12pt;left:414.68pt;width:52.71pt;">£</div><div class="clb fn1" style="top:155.13pt;left:67.73pt;width:402.65pt;">Cost</div><div class="cln fn1" style="top:166.14pt;left:67.73pt;width:349.94pt;">At 1 August 2018</div><div class="crn fn1" style="top:166.14pt;left:417.68pt;width:49.71pt;"><ix:nonFraction contextRef="A" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:PropertyPlantEquipmentGrossCost">7,456</ix:nonFraction></div><div class="cln fn1" style="top:177.14pt;left:67.73pt;width:349.94pt;">Additions</div><div class="crn fn1" style="top:177.14pt;left:417.68pt;width:49.71pt;"><ix:nonFraction contextRef="C" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:TotalAdditionsIncludingFromBusinessCombinationsPropertyPlantEquipment">1,978</ix:nonFraction></div><div class="cln fn0 sln" style="top:192.99pt;left:446.32pt;width:21.06pt;"></div><div class="cln fn1" style="top:199.16pt;left:67.73pt;width:349.94pt;">At 31 July 2019</div><div class="crn fn1" style="top:199.16pt;left:417.68pt;width:49.71pt;"><ix:nonFraction contextRef="B" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:PropertyPlantEquipmentGrossCost">9,434</ix:nonFraction></div><div class="cln fn0 sln" style="top:215pt;left:446.32pt;width:21.06pt;"></div><div class="clb fn1" style="top:221.17pt;left:67.73pt;width:352.94pt;">Depreciation and impairment</div><div class="cln fn1" style="top:232.17pt;left:67.73pt;width:349.94pt;">At 1 August 2018</div><div class="crn fn1" style="top:232.17pt;left:417.68pt;width:49.71pt;"><ix:nonFraction contextRef="A" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:AccumulatedDepreciationImpairmentPropertyPlantEquipment">4,569</ix:nonFraction></div><div class="cln fn1" style="top:243.18pt;left:67.73pt;width:349.94pt;">Depreciation charged in the year</div><div class="crn fn1" style="top:243.18pt;left:417.68pt;width:49.71pt;"><ix:nonFraction contextRef="C" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:IncreaseFromDepreciationChargeForYearPropertyPlantEquipment">1,218</ix:nonFraction></div><div class="cln fn0 sln" style="top:259.03pt;left:446.32pt;width:21.06pt;"></div><div class="cln fn1" style="top:265.19pt;left:67.73pt;width:349.94pt;">At 31 July 2019</div><div class="crn fn1" style="top:265.19pt;left:417.68pt;width:49.71pt;"><ix:nonFraction contextRef="B" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:AccumulatedDepreciationImpairmentPropertyPlantEquipment">5,787</ix:nonFraction></div><div class="cln fn0 sln" style="top:281.04pt;left:446.32pt;width:21.06pt;"></div><div class="clb fn1" style="top:287.21pt;left:67.73pt;width:402.65pt;">Carrying amount</div><div class="cln fn1" style="top:298.21pt;left:67.73pt;width:349.94pt;">At 31 July 2019</div><div class="crn fn1" style="top:298.21pt;left:417.68pt;width:49.71pt;"><ix:nonFraction contextRef="B" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:PropertyPlantEquipment">3,647</ix:nonFraction></div><div class="cln fn0 dln" style="top:314.06pt;left:446.32pt;width:21.06pt;"></div><div class="cln fn1" style="top:320.22pt;left:67.73pt;width:349.94pt;">At 31 July 2018</div><div class="crn fn1" style="top:320.22pt;left:417.68pt;width:49.71pt;"><ix:nonFraction contextRef="E" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:PropertyPlantEquipment">2,887</ix:nonFraction></div><div class="cln fn0 dln" style="top:336.07pt;left:446.32pt;width:21.06pt;"></div></div><div class="portraitPage" style="height:727pt;width:516pt;"><div class="clb fn1" style="top:31.08pt;left:46.61pt;width:423.77pt;"></div><div class="clb fn2" style="top:40.75pt;left:46.61pt;width:423.77pt;"><ix:nonNumeric contextRef="C" name="bus:EntityCurrentLegalOrRegisteredName">NEUROMEDICA LIMITED</ix:nonNumeric></div><div class="clb fn2" style="top:54.9pt;left:46.61pt;width:423.77pt;"></div><div class="clb fn3" style="top:69.04pt;left:46.61pt;width:423.77pt;">NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)</div><div class="cln fn4" style="top:80.95pt;left:46.61pt;width:420.77pt;"></div><div class="clbi fn3" style="top:86.91pt;left:46.61pt;width:423.77pt;">FOR THE YEAR ENDED 31 JULY 2019</div><div class="clb fn1" style="top:98.82pt;left:46.61pt;width:423.77pt;"></div><div class="cln fn0 sln" style="top:108.5pt;left:46.61pt;width:420.77pt;"></div><div class="cln fn0 sln" style="top:695.49pt;left:46.61pt;width:420.77pt;"></div><div class="ccn fn5" style="top:701.96pt;left:46.61pt;width:420.77pt;">- 10 -</div><div class="clb fn1" style="top:122.11pt;left:46.61pt;width:24.12pt;">4</div><div class="clb fn1" style="top:122.11pt;left:67.73pt;width:287.66pt;">Called up share capital</div><div class="crb fn1" style="top:133.12pt;left:349.39pt;width:59.56pt;">2019</div><div class="crb fn1" style="top:133.12pt;left:405.95pt;width:61.43pt;">2018</div><div class="crb fn1" style="top:144.12pt;left:349.39pt;width:59.56pt;">£</div><div class="crb fn1" style="top:144.12pt;left:405.95pt;width:61.43pt;">£</div><div class="cln fn6" style="top:144.12pt;left:468.03pt;width:0.65pt;"></div><div class="clb fn1" style="top:155.13pt;left:67.73pt;width:287.66pt;">Ordinary share capital</div><div class="clb fn1" style="top:166.14pt;left:67.73pt;width:400.78pt;">Issued and fully paid</div><div class="cln fn1" style="top:177.14pt;left:67.73pt;width:228.1pt;">1,000 Ordinary shares of £1 each</div><div class="crn fn1" style="top:177.14pt;left:352.39pt;width:56.56pt;">1,000</div><div class="crn fn1" style="top:177.14pt;left:408.95pt;width:58.43pt;">1,000</div><div class="cln fn0 dln" style="top:192.99pt;left:383.21pt;width:25.74pt;"></div><div class="cln fn0 dln" style="top:192.99pt;left:441.64pt;width:25.74pt;"></div><div class="clb fn1" style="top:210.16pt;left:46.61pt;width:24.12pt;">5</div><div class="clb fn1" style="top:210.16pt;left:67.73pt;width:400.78pt;">Operating lease commitments</div><div class="cln fn6" style="top:210.16pt;left:466.16pt;width:0.65pt;"></div><div class="clb fn1" style="top:232.17pt;left:67.73pt;width:400.78pt;">Lessee</div><div class="cln" style="top:243pt;left:68pt;width:398pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:</span></p></div><div class="crb fn1" style="top:263.65pt;left:349.39pt;width:59.56pt;">2019</div><div class="crb fn1" style="top:263.65pt;left:405.95pt;width:61.43pt;">2018</div><div class="crb fn1" style="top:274.66pt;left:349.39pt;width:59.56pt;">£</div><div class="crb fn1" style="top:274.66pt;left:405.95pt;width:61.43pt;">£</div><div class="cln fn6" style="top:274.66pt;left:468.03pt;width:0.65pt;"></div><div class="crn fn1" style="top:296.67pt;left:352.39pt;width:56.56pt;"><ix:nonFraction contextRef="B" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:FutureMinimumLeasePaymentsUnderNon-cancellableOperatingLeases">9,703</ix:nonFraction></div><div class="crn fn1" style="top:296.67pt;left:408.95pt;width:58.43pt;"><ix:nonFraction contextRef="E" decimals="0" scale="0" unitRef="GBP" format="ixt:numcommadot" name="core:FutureMinimumLeasePaymentsUnderNon-cancellableOperatingLeases">19,540</ix:nonFraction></div><div class="cln fn0 dln" style="top:312.52pt;left:383.21pt;width:25.74pt;"></div><div class="cln fn0 dln" style="top:312.52pt;left:441.64pt;width:25.74pt;"></div><div class="clb fn1" style="top:329.69pt;left:46.61pt;width:24.12pt;">6</div><div class="clb fn1" style="top:329.69pt;left:67.73pt;width:402.65pt;">Parent company</div><div class="cln" style="top:352pt;left:68pt;width:400pt;text-align:justify;font-family:Arial;font-size:7.8pt;"><p style="margin-top:0.00px;margin-bottom:0.00px;text-align:Left;"><span class="fn1">The company is under the control of N2 Holdings Ltd, a company registered in England &amp; Wales with company number 10267080, who owns 100% of the issued share capital.</span></p></div></div><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="B" name="bus:EndDateForPeriodCoveredByReport">2019-07-31</ix:nonNumeric><ix:nonNumeric contextRef="B" name="bus:StartDateForPeriodCoveredByReport">2018-08-01</ix:nonNumeric><ix:nonNumeric contextRef="C" name="bus:EntityDormantTruefalse">false</ix:nonNumeric><ix:nonNumeric contextRef="C" name="bus:EntityTradingStatus"></ix:nonNumeric><ix:nonNumeric contextRef="B" format="ixt:datelonguk" name="aurep:DateAuditorsReport">25 March 2020</ix:nonNumeric><ix:nonNumeric contextRef="C_AT_AU" name="bus:LegalFormEntity"></ix:nonNumeric><ix:nonNumeric contextRef="C" name="bus:NameProductionSoftware">CCH Software</ix:nonNumeric><ix:nonNumeric contextRef="C_AV_AW" name="bus:ApplicableLegislation"></ix:nonNumeric><ix:nonNumeric contextRef="C" name="bus:VersionProductionSoftware">CCH Accounts Production 2019.301</ix:nonNumeric><ix:nonNumeric contextRef="C_AX_AY" name="bus:AccountingStandardsApplied"></ix:nonNumeric><ix:nonNumeric contextRef="C_AZ_BA" name="bus:AccountsStatusAuditedOrUnaudited"></ix:nonNumeric><ix:nonNumeric contextRef="C" name="bus:DescriptionPrincipalActivities">No description of principal activity</ix:nonNumeric><ix:nonNumeric contextRef="C" name="bus:ScopeAccounts"></ix:nonNumeric><ix:nonNumeric contextRef="C_3_4" name="bus:NameEntityOfficer">Dr N P S Bajaj</ix:nonNumeric><ix:nonNumeric contextRef="C_3_6" name="bus:NameEntityOfficer">Dr N C Timberlake</ix:nonNumeric><ix:nonNumeric contextRef="C_BC_BD" name="bus:AccountsTypeFullOrAbbreviated"></ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="https://xbrl.frc.org.uk/FRS-102/2019-01-01/FRS-102-2019-01-01.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C"><xbrli:entity><xbrli:identifier scheme="http://www.companieshouse.gov.uk/">07316989</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3_4"><xbrli:entity><xbrli:identifier scheme="http://www.companieshouse.gov.uk/">07316989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bus:EntityOfficersDimension">bus:Director1</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3_6"><xbrli:entity><xbrli:identifier scheme="http://www.companieshouse.gov.uk/">07316989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bus:EntityOfficersDimension">bus:Director2</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="B"><xbrli:entity><xbrli:identifier scheme="http://www.companieshouse.gov.uk/">07316989</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="E"><xbrli:entity><xbrli:identifier scheme="http://www.companieshouse.gov.uk/">07316989</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="B_F_AE"><xbrli:entity><xbrli:identifier scheme="http://www.companieshouse.gov.uk/">07316989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="core:FinancialInstrumentCurrentNon-currentDimension">core:CurrentFinancialInstruments</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="E_F_AE"><xbrli:entity><xbrli:identifier scheme="http://www.companieshouse.gov.uk/">07316989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="core:FinancialInstrumentCurrentNon-currentDimension">core:CurrentFinancialInstruments</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="B_AF_AG"><xbrli:entity><xbrli:identifier scheme="http://www.companieshouse.gov.uk/">07316989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="core:EquityClassesDimension">core:ShareCapital</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="E_AF_AG"><xbrli:entity><xbrli:identifier scheme="http://www.companieshouse.gov.uk/">07316989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="core:EquityClassesDimension">core:ShareCapital</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="B_AF_AH"><xbrli:entity><xbrli:identifier scheme="http://www.companieshouse.gov.uk/">07316989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="core:EquityClassesDimension">core:RetainedEarningsAccumulatedLosses</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="E_AF_AH"><xbrli:entity><xbrli:identifier scheme="http://www.companieshouse.gov.uk/">07316989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="core:EquityClassesDimension">core:RetainedEarningsAccumulatedLosses</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D_AF_AG"><xbrli:entity><xbrli:identifier scheme="http://www.companieshouse.gov.uk/">07316989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="core:EquityClassesDimension">core:ShareCapital</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D_AF_AH"><xbrli:entity><xbrli:identifier scheme="http://www.companieshouse.gov.uk/">07316989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="core:EquityClassesDimension">core:RetainedEarningsAccumulatedLosses</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D"><xbrli:entity><xbrli:identifier scheme="http://www.companieshouse.gov.uk/">07316989</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="F_AF_AH"><xbrli:entity><xbrli:identifier scheme="http://www.companieshouse.gov.uk/">07316989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="core:EquityClassesDimension">core:RetainedEarningsAccumulatedLosses</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="F"><xbrli:entity><xbrli:identifier scheme="http://www.companieshouse.gov.uk/">07316989</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_AF_AH"><xbrli:entity><xbrli:identifier scheme="http://www.companieshouse.gov.uk/">07316989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="core:EquityClassesDimension">core:RetainedEarningsAccumulatedLosses</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7_AP"><xbrli:entity><xbrli:identifier scheme="http://www.companieshouse.gov.uk/">07316989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="core:PropertyPlantEquipmentClassesDimension">core:FurnitureFittings</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="A"><xbrli:entity><xbrli:identifier scheme="http://www.companieshouse.gov.uk/">07316989</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_AT_AU"><xbrli:entity><xbrli:identifier scheme="http://www.companieshouse.gov.uk/">07316989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bus:LegalFormEntityDimension">bus:PrivateLimitedCompanyLtd</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_AV_AW"><xbrli:entity><xbrli:identifier scheme="http://www.companieshouse.gov.uk/">07316989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bus:ApplicableLegislationDimension">bus:SmallCompaniesRegimeForAccounts</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_AX_AY"><xbrli:entity><xbrli:identifier scheme="http://www.companieshouse.gov.uk/">07316989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bus:AccountingStandardsDimension">bus:FRS102</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_AZ_BA"><xbrli:entity><xbrli:identifier scheme="http://www.companieshouse.gov.uk/">07316989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bus:AccountsStatusDimension">bus:AuditExemptWithAccountantsReport</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_BC_BD"><xbrli:entity><xbrli:identifier scheme="http://www.companieshouse.gov.uk/">07316989</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bus:AccountsTypeDimension">bus:FullAccounts</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="GBP"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit></ix:resources></ix:header></div></body></html>